Edit
Arvelle Therapeutics - Angelini Pharma Company
https://www.arvelletx.com/Last activity: 07.07.2022
Active
We are a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders.
Part of Angelini Pharma.
Part of Angelini Pharma.
Location: Switzerland, Zug
Employees: 51-200
Valuation: $960M
Founded date: 2019
Investors 7
| Date | Name | Website |
| - | H.I.G. Cap... | higcapital... |
| - | H.I.G. Eur... | higeurope.... |
| - | H.I.G. Bio... | higbio.com |
| - | Andera Par... | anderapart... |
| - | Eight Road... | eightroads... |
| - | H.I.G. Cap... | hig.com/ |
| - | Life Scien... | lspvc.com |
Mentions in press and media 11
| Date | Title | Description |
| 07.07.2022 | Novo Nordisk workers in Korea protest after breakdown in salary and perks negotiations — report | With a team of Axovant veterans leading the way, CNS startup Arvelle Therapeutics is nearing approval for licensed epilepsy med cenobamate in the EU after snagging an FDA approval in late 2019. Looking to take its first med to market, Arvel... |
| 05.01.2021 | Andera sells its Life Sciences’ portfolio company Arvelle Therapeutics | |
| 04.01.2021 | Arvelle Therapeutics exits at a valuation of $960 million | Arvelle Therapeutics is responsible for developing and commercialising cenobamate in the European market. Cenobamate is an investigational antiepileptic drug for treating patients suffering from CNS disorders and was discovered by SK Biopha... |
| 04.01.2021 | Arvelle Therapeutics exits at a valuation of $960 million | |
| 14.09.2020 | Arvelles Präparat darf in Deutschland für Härtefälle verwendet werden | Mit der Entscheidung des Bundesinstituts erreicht das biopharmazeutische Startup, das sich auf die Entwicklung innovativer Therapien für Patienten mit Erkrankungen des zentralen Nervensystems konzentriert, einen weiteren wichtigen Meilenste... |
| 14.09.2020 | Arvelles Präparat darf in Deutschland für Härtefälle verwendet werden | |
| 20.08.2020 | First patients to soon benefit from Arvelle Therapeutics’ therapy | Arvelle Therapeutics is an emerging biopharmaceutical company responsible for the development and commercialisation of cenobamate – an investigational antiepileptic drug for treating patients suffering from CNS disorders – in the European m... |
| 20.08.2020 | First patients to soon benefit from Arvelle Therapeutics’ therapy | |
| 03.04.2020 | Arvelle Therapeutics’ antiepileptic drug is a step closer to market entry | |
| 03.04.2020 | Arvelle Therapeutics’ antiepileptic drug is a step closer to market entry | Arvelle Therapeutics, an emerging biopharmaceutical company, is focused on bringing innovative treatments to patients suffering from CNS disorders. Arvelle is developing cenobamate, an investigational antiepileptic drug for the adjunctive t... |
Show more